ArticleFrontiers in oncology2026
Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Real-world data on tyrosine kinase inhibitor (TKI) use in chronic myeloid leukemia (CML) from the Middle East remain limited. We evaluated treatment patterns, molecular responses, treatment-free remission (TFR), and safety among Omani patients with chronic-phase CML. Methods: In this retrospective single-center study, adult patients (≥18 years) with chronic-phase CML treated with TKIs between January 2008 and September 2024 were included. Demographics, Sokal risk, treatment lines, molecular responses, TFR, and adverse drug reactions (ADRs) were analyzed. Results: Among 112 patients (mean age 43.7 ± 15.4 years), 45% had low Sokal risk, 43% intermediate, and 12% high risk. Imatinib was first-line therapy in 88.4%, achieving major molecular response (MMR) in 51%, with a median time to MMR of 21 months. In contrast, second-line TKIs demonstrated higher efficacy, with MMR rates of 79.2% for nilotinib and 54.4% for dasatinib, and shorter time to response (12 vs 23.2 months, respectively). Successful TFR was maintained in 17% of imatinib-treated patients after two years and in 83.3% of second-line patients after 36 months. ADRs were mainly gastrointestinal (28.5%), musculoskeletal (28.0%), dermatologic (20.8%), and hematologic (8.7%). Grade 3-4 events occurred in 5%, leading to TKI switching. Discontinuations were primarily due to loss of response, ADRs, or planned TFR. Conclusion: In this real-world cohort, first-line imatinib provided acceptable but slower and less frequent molecular responses compared with second-generation TKIs. Higher TFR maintenance rates were observed with second-generation TKIs, although interpretation is limited by small patient numbers. These findings support a response-guided, risk-adapted approach to TKI selection and highlight the need to expand access to second-generation TKIs to optimize long-term outcomes in CML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.